Kidney Cancer Weekly

July 29, 2024

Videos

Peer-to-Peer Clinical Conversations

Durvalumab Plus Guadecitabine in Metastatic Kidney Cancer: Phase 1/2 Trial Results - Yousef Zakharia

Yousef Zakharia

Pedro Barata interviews Yousef Zakharia about a phase 1/2 trial combining durvalumab and guadecitabine in metastatic kidney cancer.

Socioeconomic Disparities Drive Alarming Racial Gaps in Kidney Cancer Patient Survival Rates - Nirmish Singla

Nirmish Singla

Nirmish Singla presents research on socioeconomic determinants and racial disparities in renal cell carcinoma.

Beyond the Abstracts

Avoiding "Needless" Nephrectomy: What Is the Role of Small Renal Mass Biopsy in 2024? - Beyond the Abstract

Immunomodulatory Response to Neoadjuvant Nivolumab in Non-Metastatic Clear Cell Renal Cell Carcinoma - Beyond the Abstract

Conference Coverage

ASCO GU 2024: Development of a Patient-Centered HRQOL Measure for Metastatic RCC: A Three-Phase Study

ASCO 2024: Biomarker Analyses in Patients with Advanced Renal Cell Carcinoma from the Phase 3 CLEAR Trial

AUA 2024: Risk Stratification for Adjuvant Therapy with High Risk RCC

EAU 2024: Adjuvant Immunotherapy After pT3a F IV /N0 at Nephrectomy: Is That Real High-Risk for All? Yes

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Research on molecular characteristics of ADME-related genes in kidney renal clear cell carcinoma.

Genotype Phenotype Correlation of Renal Tumors in the Cancer Genome Atlas Database.

Surgeon Skill and Perioperative Outcomes in Robot-Assisted Partial Nephrectomy

Systemic therapies and primary tumour downsizing in renal cell carcinoma: a real-world comparison of anti-angiogenic and immune checkpoint inhibition regimens.

Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab.

Effective symptom relief through continuous integration of palliative care in advanced renal cell carcinoma patients: comprehensive measurement using the palliative care base assessment.

Identifying the facilitators and barriers to implementation of renal tumour biopsy in the diagnostic pathway for small renal masses.

A comparative analysis of fear of cancer recurrence in patients with small renal masses: Active surveillance versus cryoablation.

The Current Application and Future Potential of Artificial Intelligence in Renal Cancer.

Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.

Frequency and clinicopathologic features of renal low-grade oncocytic tumour and eosinophilic vacuolated tumour: reclassification of 605 eosinophilic tumours including patients managed with active surveillance.

Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer.

Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer.

Effect of Treatment of Residual Disease after Immunotherapy-Based Combinations on Complete Response Rate of Patients with Metastatic Renal Cell Carcinomas - Beyond the Abstract

Delphi Consensus on Stereotactic Ablative Radiotherapy for Oligometastatic and Oligoprogressive Renal Cell Carcinoma-A European Society for Radiotherapy and Oncology Study Endorsed by the European Association of Urology - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC